SS and SR patients had almost equal percentages of T-lymphocytes (CD3+) expressing CD18+ (7.0 ± 0.8% in SS vs. 7.6 ± 1.4% in SR group, p = 0.92, Figure 3A). This evidence concerns the gene ITGB2 and synovial sarcoma.